Clinical Trial Management Services Market Size, Share & Trends Analysis Report By Services (Clinical Trial Monitoring, Regulatory Submissions), By Industry, By Indication, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global clinical trial management services market was valued at USD 27.1 billion in 2021. It is expected to expand at a compound annual growth rate (CAGR) of 7.5% from 2022 to 2030. The rising number of clinical trials, technological advancement in clinical trial monitoring, and stringent regulations pertaining to data management & security are the key factors driving the market growth. Furthermore, the COVID-19 pandemic disrupted the clinical research scenario in the year 2020. The crisis led to the momentary closure of clinical studies across the globe, which resulted in negative growth in 2020.

However, growth in the adoption of virtual technologies such as remote monitoring, video visits, phone visits, and EHR by several CROs and research sites has led to a rebound of revenues across the clinical trial management services market by 2021. According to a survey conducted by Oracle, 82% of respondents consider the new clinical trial approaches specifically referring to virtual technologies. The surveyed companies integrated the new technologies during the pandemic which led to improved clinical trial research methods and results.

The COVID-19 recovery strategies have spurred pharmaceuticals & biopharmaceutical companies to use technology to make clinical trials less site-centric and more patient-centric. The new trials are decentralized, digitized, and diversified. Moreover, the conduct and management of remote clinical trials have been accelerated by the pandemic. The use of smart wearables, which may transfer data straight to a central database, has made it possible to collect clinical data from patients utilizing integrated technology. Hence, the aforementioned factors have significantly boosted the growth of the clinical trial management services market during the forecast period.

FDA has already been crucial in assisting the response activities throughout this pandemic and has assisted sponsors in guaranteeing participant safety while adhering to GCP standards. The new laws permit the use of electronic consenting for remote data gathering applications. In addition, there’s a provision to conduct virtual clinical sessions and ship the investigational product to the participant’s home. This has made it feasible to speed up the clinical trial participation process and restart the conduct of the trials, which had come to a standstill. The new law would simplify clinical trials in the near coming years, thus supporting the industry’s growth.

Services Insights

The clinical trial monitoring segment accounted for the largest revenue share of 31.6% in 2021. The rising number of clinical trials and technological advancements in trial monitoring are key factors driving the growth. Technology enablement is essential for transforming trial monitoring in a number of ways. This includes early signal detection across patient safety and eligibility, automated key risk indicator (KRI) management, and fully auditable and traceable workflows to manage risks at the study, site, and patient levels.

Early signal identification, subject-level data analysis, and process automation are all approaches to accelerate clinical trials and have a number of significant advantages. Some of these advantages include real-time visibility and automatic monitoring identification. In addition to improving clinical monitoring, these techniques can reduce the overall cost of clinical monitoring for a clinical trial by as much as 40%. This is key to growth for pharmaceutical companies as R&D remains a top priority for most global firms.

Medical writing is anticipated to register the fastest CAGR of 10.1% during the forecast period. An increase in the expiration of several essential patents remains key to the growth of the record number of new clinical trials. Medical writing is a key support activity for a successful clinical trial. It involves the creation of medical documents as an integral part of clinical research. One of the key factors driving the growth of the medical writing segment is an increase in demand for the regulatory frameworks of clinical trials in the pharmaceutical and biopharmaceutical industries.

Indication Insights

The oncology segment accounted for the maximum revenue share of 31.0% in 2021 and is also anticipated to register the fastest CAGR growth of over 8% from 2022 to 2030. The rise in oncology R&D investments, the increasing cancer incidences, and the growing demand for personalized medications, coupled with a surge in innovative developments in the field of oncology are the key factors driving the growth. For instance, according to the American Cancer Society, the total number of cancer cases is anticipated to rise to 1.9 million in the U.S. in 2022.

Neurology is expected to be the second most lucrative segment with a CAGR of 8.0% during the forecast timeframe, due to increasing neurological diseases. Some severe neurology diseases are dementia, stroke, and peripheral neuropathy. The rising R&D investments in neurological research remain a major promise for the growth of the market. For instance, in June 2020, as per an article published by the Commonwealth of Australia, the Australian Government invested USD 21.8 million for clinical research in treating a range of neurological disorders, including early Alzheimer’s disease, autism, and encephalitis.

Industry Insights

The pharmaceuticals segment accounted for the largest revenue share of 38.9% in 2021. This can be largely attributed to the rise in R&D investments and the development of new drugs over the past two decades. The amount spent on R&D by the pharmaceutical industry in 2019 was USD 83 billion, which is 10 times more than the amount spent in 1980. In the near future, the demand for efficacious, safe, and cost-effective medicine is expected to fuel the development of enhanced pharmaceutical drugs. This would drive the demand for clinical trial management services due to investment in innovative drugs in clinical trials.

The biopharmaceuticals segment is anticipated to register the fastest CAGR of 7.8% during the forecast period. The increasing pipeline of biopharma products, a rise in the prevalence of rare diseases, and a growing number of biological clinical trials are a few of the prominent factors anticipated to support the segment’s lucrative growth. Furthermore, the surge in the number of companies focusing on the development of novel biologics is likely to further aid the growth. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) estimates that in 2018, the global research-based biopharmaceutical industry spent about USD 179 billion on R&D. By 2022, this figure is projected to increase to USD 202 billion.

Regional Insights

North America accounted for the largest revenue share of 35.3% in 2021. The growing prevalence of chronic diseases like cancer and diabetes, the rise in the demand for novel therapies, and the increase in the number of contract research organizations across the region remain prominent growth drivers. Furthermore, the rise in the number of clinical studies, especially in the U.S. is also anticipated to support the lion’s share of the North American region in the global market.

Asia Pacific is projected to be the fastest-growing region with a CAGR of 8.5% over the forecast period. The major factors driving the growth include favorable government policies, cheap labor costs, the presence of a diverse patient pool, and awareness about clinical trial services. Furthermore, growing R&D investments and relatively lower costs associated with clinical trials remain key drivers to its burgeoning growth For instance, the clinical trial costs in China and India are 25% to 40% lower than that in the developed regions. Furthermore, Asia has a lower percentage of EMA critical findings and the US FDA official actions compared to North America, which indicates a high standard of global compliance.

Key Companies & Market Share Insights

Some of the key market players include LabCorp; IQVIA, Inc.; Syneous Health; Atlantic Research Group; and ICON Plc. The players continue to adopt a variety of strategic initiatives, such as partnerships, collaborations, mergers & acquisitions, and geographic expansions. The focus on strengthening their services and gaining a competitive advantage remains a defining trend globally. For instance, in November 2021, ICON plc announced its new partnership agreements with six study sites spread across four nations, including the U.S., Germany, Spain, and Poland. The partnership aimed at improving the scope and capabilities of its Accellacare Site Network. Some prominent players in the global clinical trial management services market include:

• Clinical Trial & Consulting Services

• Charles River Laboratories

• Med pace

• Wuxi Apptec

• SGS

• LabCorp

• IQVIA, Inc.

• Syneous Health

• Atlantic Research Group

• ICON Plc

Clinical Trial Management Services Market Report Scope

Global Clinical Trial Management Services Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018-2030. For this study, Grand View Research has segmented the global clinical trial management services market report based on services, industry, indication, and region:

• Services Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinical Trial Monitoring

  • Regulatory Submissions

  • Clinical Trial Data Management

  • Medical Writing

  • Site Management & Monitoring

  • Others

• Industry Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceuticals

  • Biopharmaceuticals

  • Medical Devices

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Immunology

  • Hematology

  • Oncology

  • Neurology

  • Dermatology

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE